Skip to Main Content

A coalition of institutional investors is submitting shareholder proposals to demand several drug makers compile reports about the risks created by high prices and, in some cases, also examine the extent to which pricing strategies propel executive compensation.

The move, which is being led by the Interfaith Center for Corporate Responsibility, is an attempt to go beyond similar efforts in years past that largely — and unsuccessfully — tried to force drug makers to justify and explain their pricing.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!